David Reynolds, LoQus23 Therapeutics CEO
UK biotech bags $43M in Series A to move Huntington's drug into first human study
LoQus23 Therapeutics has secured £35 million ($43 million) in a Series A fundraise led by Forbion and backed by the venture arm of Novartis to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
